合并资产负债表 2025年6月30日 | 编制单位 湖北广济药业股份有限公司 | | --- | | 编制单位:湖北广济药业股份有限公司 | | | 金额单位:人民币元 | | --- | --- | --- | --- | | | 川 E | 2025年6月30日 | 2024年12月31日 | | 流动负债: | 0 | | | | 短期借款 | | 431,332,408.96 | 344,244,499.36 | | 交易性金融负债 | | | | | 衍生金融负债 | | | | | 应付票据 | | 41,535,807.22 | 8,345,858.49 | | 应付账款 | | 117,026,906.62 | 112,871,737.72 | | 预收款项 | | | | | 合同负债 | | 7,260,059.51 | 5,977,632.26 | | 应付职工薪酬 | | 22,329,492.57 | 22,833,793.97 | | 应交税费 | | 8,471,676.03 | 11,209,314.45 | | 其他应付款 | | 361,794,027.73 | 80,52 ...

湖北广济药业股份有限公司 2025 年半年度财务报告 湖北广济药业股份有限公司 2025 年半年度财务报告 2025 年 08 月 1 湖北广济药业股份有限公司 2025 年半年度财务报告 湖北广济药业股份有限公司 2025 年半年度财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 编制单位：湖北广济药业股份有限公司 2025 年 06 月 30 日 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 519,982,780.81 | 307,177,265.18 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | | | | 衍生金融资产 | | | | 应收票据 | 28,405,484.63 | 38,646,556.86 | | 应收账款 | 166,649,053.96 | 174,029,671.89 | | 应收款项融资 | 4,097,632.47 | 10,514,601.56 ...

湖北广济药业股份有限公司 关于召开 2025 年第三次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 证券代码：000952 证券简称：广济药业 公告编号：2025-047 湖北广济药业股份有限公司（以下简称"公司"或"广济药业"）于 2025 年 8 月 27 日召开的第十一届董事会第十次会议审议通过了《关于召开 2025 年 第三次临时股东会的议案》，同意召开本次股东会，现将有关事项通知如下： 一、召开会议的基本情况 1、股东会届次：广济药业 2025 年第三次临时股东会 2、召集人：公司董事会，经公司第十一届董事会第十次会议审议，决定召 开公司 2025 年第三次临时股东会。 3、会议召开的合法、合规性：公司董事会认为本次股东会的召开符合有关 法律、行政法规、部门规章、规范性文件、深圳证券交易所业务规则和《公司 章程》的规定。 4、会议召开的日期和时间： （1）现场会议召开日期和时间：2025 年 9 月 18 日（星期四）下午 15:30 （2）网络投票时间：2025 年 9 月 18 日（星期四） 其中，通过深圳证券交易所交易系统进 ...

Core Viewpoint - Guangji Pharmaceutical's stock price has shown a slight increase, reflecting market activity and potential investor interest amid ongoing corporate governance issues [1] Company Overview - Guangji Pharmaceutical is primarily engaged in the research, development, production, and sales of pharmaceutical raw materials and formulations, covering various fields including vitamins and antibiotics [1] - The company is currently controlled by Changjiang Industrial Investment Group, a significant industrial investment platform in Hubei Province, which also holds stakes in multiple listed companies [1] Recent Developments - The company’s stock price is reported at 7.14 yuan, with a daily increase of 0.85%, reaching a high of 7.16 yuan and a low of 7.03 yuan during trading [1] - The total market capitalization of Guangji Pharmaceutical stands at 2.476 billion yuan, with a negative price-to-earnings ratio [1] - Recent news indicates that Xie Bin, a member of the Changjiang Industrial Investment Group's party committee, is under investigation for serious violations of discipline and law, which may impact investor sentiment [1] Financial Activity - On August 11, the net outflow of main funds for Guangji Pharmaceutical was 2.8192 million yuan, with a cumulative net outflow of 4.1344 million yuan over the past five days [1]

Core Viewpoint - Guangji Pharmaceutical (000952.SZ) has been penalized for significant financial misreporting, revealing deeper operational issues and a decline in financial health over recent years [1][2][4]. Financial Misreporting - Guangji Pharmaceutical's subsidiary, Jikang Pharmaceutical, inflated revenue by 321 million yuan through improper accounting practices, using gross method instead of net method for revenue recognition [2]. - The inflated revenue figures for 2022 included 45.6 million yuan in Q1, 137 million yuan in Q2, and 138 million yuan in Q3, representing 25.49%, 26.68%, and 20.49% of respective quarterly revenues [2]. - The company faced a fine of 1.5 million yuan from the China Securities Regulatory Commission (CSRC) and warnings issued to key executives for their roles in the misreporting [2][3]. Financial Performance Decline - Guangji Pharmaceutical reported a revenue decline to 738 million yuan in 2023, with a net loss of 140 million yuan and a gross margin drop of nearly 10 percentage points to 27.4% [5][7]. - The company has accumulated losses of 435 million yuan over two years, marking the worst performance in its 25-year history [8]. - The gross margin for the main product, high-content vitamin B2, has fallen to a historical low of 17.66% due to market oversupply and increased competition [8]. Operational Challenges - The company has been heavily reliant on its vitamin B2 products, which accounted for 82.83% of revenue in 2024, while the high-margin formulation products saw a significant revenue drop of 65.26% [8]. - Guangji Pharmaceutical's debt ratio increased from 39.58% at the end of 2022 to 64.19% by Q1 2025, indicating rising financial strain [8]. - The company is projected to incur further losses of 67 million to 83.5 million yuan in the first half of 2025, suggesting ongoing downward trends [8]. Strategic Outlook - The company aims to pursue a dual strategy of internal expansion and external acquisitions to revitalize its business model, focusing on vitamin B products and new product lines [9]. - There are concerns regarding the impact of past governance issues and financial misreporting on future operations, including potential investor claims and reputational damage [10].

Group 1 - The stock price of Guangji Pharmaceutical is reported at 6.97 yuan, down 0.71% from the previous trading day, with a trading volume of 0.53 billion yuan [1] - Guangji Pharmaceutical operates in the chemical pharmaceutical industry, primarily producing vitamin B series products and pharmaceutical preparations, and is a major global supplier of vitamin B2 [1] - Recent announcements indicate that the subsidiary Jikang Pharmaceutical improperly recognized revenue using the total amount method, leading to overreported revenues of 45.6016 million yuan, 137 million yuan, and 138 million yuan for the three quarterly reports of 2022 [1] Group 2 - The Hubei Securities Regulatory Bureau imposed a fine of 1.5 million yuan on the company, and relevant responsible persons were also penalized [1] - The company is expected to report a net loss of 295 million yuan for 2024, with anticipated losses of 67 million to 83.5 million yuan for the first half of 2025 [1] - Data shows that the net outflow of main funds for Guangji Pharmaceutical is 6.528 million yuan [1]

Core Viewpoint - The financial misconduct of Guangji Pharmaceutical has been revealed, leading to significant losses and operational decline, raising concerns about the company's governance and future viability [1][4]. Financial Misconduct - Guangji Pharmaceutical's subsidiary, Jikang Pharmaceutical, used the total amount method to recognize revenue instead of the net amount method, resulting in inflated revenues [2]. - The inflated revenues for 2022 included: Q1 by 45.6 million (25.49%), Q2 by 137 million (26.68%), and Q3 by 138 million (20.49%) [2]. - The company faced a penalty of 1.5 million yuan, with the chairman and CFO receiving individual fines of 800,000 yuan each [2]. Operational Decline - The company reported a net loss of 295 million yuan in 2024, a decline of over 110% year-on-year, with cumulative losses of 435 million yuan over two years [1][3]. - Revenue for 2024 was only 639 million yuan, down 13.42%, with core product revenue dropping by 65.26% to 61.43 million yuan [3]. - Research and development expenses fell by 24% to 56.81 million yuan, constituting less than 9% of revenue [3]. Future Outlook - The company anticipates a reduced loss of 67 to 83.5 million yuan in the first half of 2025, attributed to cost-cutting and some recovery in product sales [4]. - However, challenges remain, including low capacity utilization and ongoing reductions in R&D investment, which threaten innovation and competitiveness [4][5].

Core Viewpoint - Guangji Pharmaceutical has faced administrative penalties due to improper revenue recognition practices, leading to significant financial discrepancies and losses in recent years [2][3][4]. Financial Misconduct - The company’s subsidiary, Jikang Pharmaceutical, incorrectly used the gross method for revenue recognition instead of the net method, resulting in overstated revenues of 45.6 million yuan, 137 million yuan, and 138 million yuan for the first three quarters of 2022, which accounted for 25.49%, 26.68%, and 20.49% of the respective quarterly revenues [2][3]. - The company was fined 1.5 million yuan, and the chairman and CFO were each fined 800,000 yuan for their roles in the misconduct [3]. Financial Performance - In 2024, Guangji Pharmaceutical reported a revenue of 639 million yuan, a decline of 13.42% year-on-year, marking two consecutive years of negative growth [4]. - The net loss for 2024 expanded to 295 million yuan, a 110.55% increase compared to the previous year's loss of 140 million yuan [4]. - The core product line, the formulation series, saw a dramatic decline in revenue, dropping 65.26% to 61.4 million yuan, which constituted only 9.62% of total revenue [4]. Market Conditions - The company attributed its poor performance to a downturn in the overall economic environment, reduced market demand, and lower-than-expected prices due to increased competition in the vitamin market [5]. - The subsidiary Guangji Pharmaceutical (Mengzhou) faced losses due to underutilization of its 1,000-ton capacity for vitamin B12, while Guangji Pharmaceutical (Jining) also continued to incur losses [5]. Research and Development - Research and development expenditures decreased to 56.81 million yuan in 2024, a 24% reduction, with the R&D spending as a percentage of revenue falling from 10.13% to 8.89% [5]. - The company anticipates a reduction in losses for the first half of 2025, projecting a net loss of approximately 67 million to 83.5 million yuan [5].

Group 1 - Titan Technology plans to acquire 100% of Apollo Scientific Ltd. for approximately 55.85 million yuan, enhancing its global supply chain and competitiveness in the reagent field [1] - Qianjin Pharmaceutical has received registration certificates for two drugs, enriching its product line and strengthening its position in the treatment of vitamin B12 deficiency and heart failure [2] - Meizhong Jiahe intends to raise approximately 270 million HKD through a share placement, focusing on hospital construction, medical AI, and operational funding [3] Group 2 - ST Weiming has successfully recovered 100% equity of Xiamen Weiming, resolving long-standing equity disputes and stabilizing corporate governance [4] - Guangji Pharmaceutical has been fined 1.5 million yuan for information disclosure violations, highlighting governance issues and the need for compliance to restore investor confidence [5]

证券代码：000952 证券简称：广济药业 公告编号：2025-042 湖北广济药业股份有限公司 关于 2021 年限制性股票激励计划部分限制性股票 回购注销完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 额的 0.89%。 源为公司自有资金。 深圳分公司办理完成回购注销手续。 根据《上市公司股权激励管理办法》和《湖北广济药业股份有限公司 2021 年 限制性股票激励计划》（以下简称"本激励计划""《激励计划》"）的相关规定， 湖北广济药业股份有限公司（以下简称"广济药业"或"公司"）分别于 2025 年 限制性股票激励计划部分限制性股票的议案》。鉴于本激励计划首次授予及预留授 予第二个解除限售期的解除限售条件未成就以及本激励计划激励对象中有 8 人已 离职/退休而不再具备激励资格，因此，公司对前述 141 名激励对象已获授但尚未 解除限售的限制性股票共计 310.5 万股进行回购注销。具体内容详见公司于 2025 年 4 月 28 日在指定媒体披露的《关于回购注销 2021 年限制性股票激励计划部分 限制性股票的公告》（公告编号：20 ...